Edition:
United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

22.40USD
24 Jul 2017
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$22.40
Open
$20.65
Day's High
$22.50
Day's Low
$20.32
Volume
1,089,802
Avg. Vol
1,026,506
52-wk High
$33.00
52-wk Low
$13.60

Latest Key Developments (Source: Significant Developments)

Christopher James reports 5.9 pct passive stake in Acorda Therapeutics as of June 27, 2017
Friday, 7 Jul 2017 04:10pm EDT 

July 7 (Reuters) - Acorda Therapeutics Inc ::Christopher M. James reports a 5.9 percent passive stake in Acorda Therapeutics Inc as of June 27, 2017- sec filing.  Full Article

Acorda submits new drug application to U.S. Food And Drug Administration
Thursday, 29 Jun 2017 04:01pm EDT 

June 29 (Reuters) - Acorda Therapeutics Inc ::Acorda submits new drug application to U.S. Food And Drug Administration for inbrijatm (CVT-301, levodopa inhalation powder).Acorda Therapeutics Inc - trade name for CVT-301, inbrija, has been conditionally accepted by FDA.Acorda Therapeutics Inc - co anticipates FDA to inform acorda by end of September if submission has been deemed complete and permits a full review.Acorda Therapeutics Inc - plans to file a marketing authorization application (MAA) in EUROPE for CVT-301 by end of 2017.  Full Article

Acorda Therapeutics says expects results from Tozadenant phase 3 clinical trial in Q1 2018​
Tuesday, 6 Jun 2017 06:00am EDT 

June 6 (Reuters) - Acorda Therapeutics Inc :Acorda Therapeutics Inc - expects results from an ongoing tozadenant phase 3 clinical trial in q1 2018​.Acorda Therapeutics Inc - ‍ company initiated an open-label, long-term safety study for Tozadenant in Q2 of 2017​.  Full Article

CVT-301 phase 3 data showed significantly positive results
Monday, 5 Jun 2017 04:01pm EDT 

June 5 (Reuters) - Acorda Therapeutics Inc :CVT-301 phase 3 data showed significantly improved motor function during off periods in Parkinson’s disease.Multiple secondary endpoints were supportive of primary endpoint result.Acorda plans to file new drug application (NDA) in U.S. by end of Q2 2017.CVT-301 phase 3 span-PD study met primary endpoint.  Full Article

Acorda qtrly GAAP net loss $0.41 per diluted share
Thursday, 27 Apr 2017 06:00am EDT 

April 27 (Reuters) - Acorda Therapeutics Inc ::Acorda provides financial and pipeline update for first quarter 2017.Acorda Therapeutics Inc- projected year-end cash balance greater than $200 million.Acorda Therapeutics Inc- 2017 combined research and development and SG&A operating expense guidance revised to $330 - $350 million, a reduction of about $50 million.Acorda Therapeutics Inc - qtrly GAAP net loss for quarter ended March 31, 2017, $0.41 per diluted share.Acorda Therapeutics Inc - qtrly non-gaap net loss for quarter ended march 31, 2017 $.08 per diluted share.Q1 earnings per share view $0.09, revenue view $127.3 million -- Thomson Reuters I/B/E/S.  Full Article

Acorda Therapeutics to cut 20 pct of workforce
Wednesday, 5 Apr 2017 06:00am EDT 

Acorda Therapeutics Inc : Acorda Therapeutics implements corporate restructuring . Acorda Therapeutics says corporate restructuring to reduce cost structure and focus resources on two late-stage programs, CVT-301 and Tozadenant . Acorda Therapeutics says as part of restructuring, co is reducing headcount by about 20 percent . Acorda Therapeutics says co expects to realize estimated annualized cost savings from reduction in personnel of about $21 million beginning in Q2 of 2017 . Acorda Therapeutics says estimates that it will incur about $7.6 million of pre-tax charges for severance and other costs related to restructuring . Acorda Therapeutics says co plans to file a new drug application for CVT-301 with the FDA in the second quarter of 2017 .Acorda - adoption of restructuring plan follows invalidation of certain patents pertaining to Ampyra (dalfampridine) extended release tablets, 10 mg.  Full Article

U.S. district court invalidates four Acorda Therapeutics Ampyra patents
Friday, 31 Mar 2017 12:31pm EDT 

Acorda Therapeutics Inc : U.S. district court issues decision to invalidate four Ampyra patents; company will appeal ruling .Company has developed contingency plans to address its business needs and objectives in event of a loss of Ampyra exclusivity.  Full Article

Acorda announces long-term safety data for CVT-301
Wednesday, 29 Mar 2017 06:00am EDT 

Acorda Therapeutics Inc : Acorda announces long-term safety data for cvt-301 . New drug application (NDA) submission planned by end Q2 2017 . Plans to file a marketing authorization application (MAA) in europe by end of 2017 . Pulmonary function measures over 12 months comparable between CVT-301 and observational control group .Acorda therapeutics - there was one death in study, a drowning in CVT-301 84 MG group, judged by investigator to be not related to study drug.  Full Article

Scopia Capital Management reports 12 pct passive stake in Acorda Therapeutics
Friday, 10 Mar 2017 04:59pm EST 

Scopia Capital Management LP: Scopia Capital Management LP reports 12 percent passive stake in Acorda Therapeutics Inc as of Feb 28 - SEC filing .Scopia Capital Management LP - previously reported a 9.8 percent passive stake in Acorda Therapeutics as of Dec 31, 2016.  Full Article

Acorda Therapeutics entered into settlement agreement with Apotex Corp, Apotex Inc on Feb. 8
Friday, 10 Feb 2017 07:57am EST 

Acorda Therapeutics Inc : Acorda Therapeutics Inc - on Feb 8, 2017, Acorda Therapeutics, inc entered into settlement agreement with Apotex Corporation and Apotex Inc-sec filing . Acorda Therapeutics- as result of settlement agreement, co will be permitted to market generic version of ampyra in united states at specified date in 2025 . Acorda Therapeutics Inc - settlement to resolve pending patent litigation brought by company against Apotex involving ampyra extended-release tablets . Acorda Therapeutics - parties will request court enter consent order, in which it will dismiss company's litigation against apotex referred to above .Acorda Therapeutics Inc - details of settlement are confidential.  Full Article

BRIEF-Christopher James reports 5.9 pct passive stake in Acorda Therapeutics as of June 27, 2017

* Christopher M. James reports a 5.9 percent passive stake in Acorda Therapeutics Inc as of June 27, 2017- sec filing Source text (http://bit.ly/2tz6Pgg) Further company coverage: